VitriVax, a Boulder, Colorado- and Boston, Massachusetts-based developer of a novel stabilization and delivery platform for vaccines and therapeutics, closed its Series A financing round with Adjuvant Capital.
The amount of the deal was not disclosed. Concurrent with the financing, Adjuvant Capital’s Charlie Petty and Glenn Rockman have joined VitriVax’s board of directors.
The company intends to use the proceeds to develop and commercialize technology with the potential to eliminate barriers to global vaccine administration, extending their life-saving benefits to underserved populations and compressing multidose regimens into a single shot.
Formed by Dr. Robert Garcea and Dr. Theodore Randolph at the University of Colorado, Boulder, and and led by CEO Matt Raider, VitraVax leverages the Atomic Layering Thermostable Antigen and Adjuvant (ALTA™) technology platform to enable the development of vaccines that can be transported and stored without complex refrigeration and temperature monitoring requirements. The platform also aims to enable full immunization with a single vaccination via timed release of antigen/adjuvant complexes weeks or months after injection.
The company uses a spray drying process to embed antigens and adjuvants in a sugar-glass matrix, protecting them against thermal and chemical degradation at temperatures as high as 70° Celsius (158° Fahrenheit) for months, as demonstrated in multiple mouse studies using HPV capsomeres as a model antigen, as well as in multiple studies with commercial partners.
VitriVax has established a number of partnerships with clinical- and commercial-stage pharmaceutical partners across a wide range of disease areas and modalities in human and animal health.
Prior to the funding from Adjuvant Capital, the research leading to the ALTA™ platform had been supported by grants from the National Institutes of Health, the State of Colorado and the Bill & Melinda Gates Foundation.
FinSMEs
07/07/2021